[article]
| Titre : |
Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects |
| Type de document : |
Texte imprimé et/ou numérique |
| Auteurs : |
David COHEN, Auteur ; Marie RAFFIN, Auteur ; Roberto CANITANO, Auteur ; Nicolas BODEAU, Auteur ; Olivier BONNOT, Auteur ; Didier PERISSE, Auteur ; Angèle CONSOLI, Auteur ; Claudine LAURENT, Auteur |
| Année de publication : |
2013 |
| Article en page(s) : |
p.167-75 |
| Langues : |
Anglais (eng) |
| Mots-clés : |
Second generation antipsychotics Childhood Adolescence AutismIntellectual disability Adverse effects Meta-analysis |
| Index. décimale : |
PER Périodiques |
| Résumé : |
Second-generation antipsychotics (SGAs) induce frequent adverse effects in children and adolescents with each compound appearing to have a specific adverse effect profile. Aripiprazole and risperidone are FDA-approved medications for behavioral disturbances associated with autism and/or intellectual disabilities (ID) in children and adolescents. Using Bayesian meta-analysis of all relevant studies (N = 8; 18 arms; 782 patients), we aimed to calculate odds ratios (OR) or mean average effects to assess efficacy, weight gain, metabolic changes, sedation, and extra-pyramidal syndrome (EPS) of the two compounds. Reporting was incomplete to assess metabolic changes. Compared to placebo, significant treatment-related increases were observed for: CGI response with aripiprazole (OR = 6.09, 95% credible interval [2.3–12.63]) and risperidone (12.8 [5.57–27.33]); weight gain with aripiprazole (OR = 6.28 [1.64–17.12]) and risperidone (7.76 [1.88–25.2]); EPS with risperidone (OR = 3.72 [1.73–7.22]); and somnolence/sedation with aripiprazole (OR = 25.76 [1.29–112.3]) and risperidone (9.63 [3.52–22.79]). There were no significant differences between active compounds. We conclude that short term efficacy of risperidone and aripiprazole are similar for behavioral disturbances associated with autism and/or ID, and that secondary effects are frequent. More research should be conducted on metabolic changes as current literature is lacking compared to other indications in youths. |
| En ligne : |
http://dx.doi.org/10.1016/j.rasd.2012.08.001 |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=180 |
in Research in Autism Spectrum Disorders > 7-1 (January 2013) . - p.167-75
[article] Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects [Texte imprimé et/ou numérique] / David COHEN, Auteur ; Marie RAFFIN, Auteur ; Roberto CANITANO, Auteur ; Nicolas BODEAU, Auteur ; Olivier BONNOT, Auteur ; Didier PERISSE, Auteur ; Angèle CONSOLI, Auteur ; Claudine LAURENT, Auteur . - 2013 . - p.167-75. Langues : Anglais ( eng) in Research in Autism Spectrum Disorders > 7-1 (January 2013) . - p.167-75
| Mots-clés : |
Second generation antipsychotics Childhood Adolescence AutismIntellectual disability Adverse effects Meta-analysis |
| Index. décimale : |
PER Périodiques |
| Résumé : |
Second-generation antipsychotics (SGAs) induce frequent adverse effects in children and adolescents with each compound appearing to have a specific adverse effect profile. Aripiprazole and risperidone are FDA-approved medications for behavioral disturbances associated with autism and/or intellectual disabilities (ID) in children and adolescents. Using Bayesian meta-analysis of all relevant studies (N = 8; 18 arms; 782 patients), we aimed to calculate odds ratios (OR) or mean average effects to assess efficacy, weight gain, metabolic changes, sedation, and extra-pyramidal syndrome (EPS) of the two compounds. Reporting was incomplete to assess metabolic changes. Compared to placebo, significant treatment-related increases were observed for: CGI response with aripiprazole (OR = 6.09, 95% credible interval [2.3–12.63]) and risperidone (12.8 [5.57–27.33]); weight gain with aripiprazole (OR = 6.28 [1.64–17.12]) and risperidone (7.76 [1.88–25.2]); EPS with risperidone (OR = 3.72 [1.73–7.22]); and somnolence/sedation with aripiprazole (OR = 25.76 [1.29–112.3]) and risperidone (9.63 [3.52–22.79]). There were no significant differences between active compounds. We conclude that short term efficacy of risperidone and aripiprazole are similar for behavioral disturbances associated with autism and/or ID, and that secondary effects are frequent. More research should be conducted on metabolic changes as current literature is lacking compared to other indications in youths. |
| En ligne : |
http://dx.doi.org/10.1016/j.rasd.2012.08.001 |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=180 |
|  |
Faire une suggestion Affiner la rechercheRisperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects / David COHEN in Research in Autism Spectrum Disorders, 7-1 (January 2013)
Trouble bipolaire : définition et controverse : Trouble bipolaire pédiatrique : controverse / Angèle CONSOLI
